BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/31/2025 5:47:44 AM | Browse: 74 | Download: 316
 |
Received |
|
2025-08-27 23:06 |
|
Peer-Review Started |
|
2025-08-27 23:06 |
|
First Decision by Editorial Office Director |
|
2025-09-04 06:56 |
|
Return for Revision |
|
2025-09-04 06:56 |
|
Revised |
|
2025-09-13 13:55 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-06 02:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-06 06:31 |
|
Articles in Press |
|
2025-11-06 06:31 |
|
Edit the Manuscript by Language Editor |
|
2025-11-09 02:29 |
|
Typeset the Manuscript |
|
2025-12-19 02:42 |
|
Publish the Manuscript Online |
|
2025-12-31 05:47 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Initial lurasidone dosing in acute schizophrenia: Pragmatic and trajectory-aware clinical implications
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yang Liu and Tao Liu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tao Liu, Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing 100053, China. liu_t2019@163.com |
| Key Words |
Lurasidone; Schizophrenia; Antipsychotic agents; Treatment outcome; Akathisia; Body weight |
| Core Tip |
Choosing a starting dose may influence the early clinical trajectory in acute schizophrenia. In a pragmatic randomized study, 80 mg/day for the first week led to more rapid improvement in Positive and Negative Syndrome Scale positive symptoms than 40 mg/day, with similar discontinuation for adverse events and no short-term metabolic penalty. Clinicians may prioritize speed with 80 mg/day when tolerated, or start at 40 mg/day when akathisia risk is a concern, coupled with a day-7 review for escalation. Open-label design and dose convergence temper causal claims, but initial dose selection may shape the early trajectory. |
| Publish Date |
2025-12-31 05:47 |
| Citation |
Liu Y, Liu T. Initial lurasidone dosing in acute schizophrenia: Pragmatic and trajectory-aware clinical implications. World J Psychiatry 2026; 16(1): 113548 |
| URL |
https://www.wjgnet.com/2220-3206/full/v16/i1/113548.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v16.i1.113548 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
